Trial Profile
A Phase 1 Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Febuxostat in Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Verinurad (Primary) ; Febuxostat
- Indications Gout; Heart failure; Hyperuricaemia; Kidney disorders; Renal failure; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Ardea Biosciences
- 19 Sep 2020 Results (n=141) of pooled analysis from NCT02246673, NCT02317861 and NCT01883167 assessing clinically relevant covariates for febuxostat pharmacokinetics on on Asian race and bodyweight, published in the Clinical Pharmacokinetics
- 30 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.